Added to YB: 2024-11-27
Pitch date: 2024-11-26
NVO [bullish]
Novo Nordisk A/S
-53.99%
current return
Author Info
Long-Term Pick shares in-depth stock analysis on high-quality stocks with growth potential. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 100.29
Price Target
124.92 (+169%)
Dividend
3.91%
EV/EBITDA
8.10
P/E
11.43
EV/Sales
4.31
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: Diabetes Care Leader Below Fair Price
NVO: Leader in diabetes/obesity care with 34% global market share. Q3 revenue +23% YoY to DKK 204.7B. Strong pipeline, 54% GLP-1 market share. Expanding into new therapeutic areas. Trades at attractive PEG ratio. Risks: competition, supply constraints, pricing pressure. 46% upside potential.
Read full article (11 min)